The impact of Oral Anticoagulants on Idiopathic Pulmonary Fibrosis Risk and Prognosis: A Population Study

Francesca Gonnelli* (Corresponding Author), Heath Heatley, Ursie Smith, Nevaashni Eleangovan, Vidya Navarantam, John Townend, Tamera J. Corte, David Price, Victoria Carter, Martina Bonifazi, Caitlin C. Fermoyle, Richard Hubbard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Oral anticoagulant (OAC) use in idiopathic pulmonary fibrosis (IPF) is largely linked to comorbidities, not a direct causal relationship with IPF. OACs, especially warfarin, are not harmful in IPF when prescribed appropriately for comorbidities.
Original languageEnglish
JournalEuropean Respiratory Journal
Publication statusAccepted/In press - 4 Jul 2025

Fingerprint

Dive into the research topics of 'The impact of Oral Anticoagulants on Idiopathic Pulmonary Fibrosis Risk and Prognosis: A Population Study'. Together they form a unique fingerprint.

Cite this